In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 669 ( 2022-11-02)
Abstract:
Immune checkpoint blockade (ICB) has revolutionized treatment for many patients with cancer, but not all patients benefit. Thus, strategies to enhance ICB are essential to broaden the population of patients who may benefit. Here, Stanczak et al. showed that tumor hypersialylation drives immune escape and cancer progression. Targeting this particular type of glycosylation with an antibody-sialidase conjugate improved antitumor immune responses that were further enhanced by combination ICB. Thus, desialylation may be an effective approach to augment ICB.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abj1270
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Bookmarklink